The letters targeted what agency officials called “junk listings” on ... “To the contrary, robust patent listings are inherently pro-competitive.” An FTC official declined to answer ...
What Happened: The FTC is disputing “junk patent listings” for diabetes ... Other companies targeted include Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) and Teva Pharmaceutical Industries ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
This follows a similar move the FTC made in November involving 100 patents filed by pharma companies. The latest spate of “junk patent” listings include medicines for diabetes, asthma, COPD, and ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining ... they rely on,” FTC Chair Lina Khan ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
But other companies argue that the FTC’s accusation that their patents are junk isn’t accurate. McGrevy: So, what’s next? Gabriel: If drug manufacturers don’t remove their junk patent listings, ...
Over the last eight months, the US Federal Trade Commission (FTC) has focused on what it characterizes as “improper” Orange Book listings ... targeted by the FTC to delist their patents ...
Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, and those can be pretty expensive. But the FTC hasn’t announced if ...